Cargando…
贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000572/ https://www.ncbi.nlm.nih.gov/pubmed/23769349 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.10 |
_version_ | 1783331773273341952 |
---|---|
collection | PubMed |
description | We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44, 730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects. |
format | Online Article Text |
id | pubmed-6000572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60005722018-07-06 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 Zhongguo Fei Ai Za Zhi 病例报道 We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44, 730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects. 中国肺癌杂志编辑部 2013-06-20 /pmc/articles/PMC6000572/ /pubmed/23769349 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.10 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 病例报道 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
title | 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
title_full | 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
title_fullStr | 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
title_full_unstemmed | 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
title_short | 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
title_sort | 贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾 |
topic | 病例报道 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000572/ https://www.ncbi.nlm.nih.gov/pubmed/23769349 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.10 |
work_keys_str_mv | AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù AT bèifázhūdānkàngzhǎngqīwéichízhìliáowǎnqīfēixiǎoxìbāofèiái39gèyuèdebìnglìbàogàojíxiāngguānwénxiànhuígù |